Endoscopic hemostasis followed by preventive transarterial embolization in high-risk patients with bleeding peptic ulcer : 5-year experience by Kaminskis, Aleksejs et al.
RESEARCH ARTICLE Open Access
Endoscopic hemostasis followed by
preventive transarterial embolization in
high-risk patients with bleeding peptic
ulcer: 5-year experience
Aleksejs Kaminskis1* , Patricija Ivanova1, Aina Kratovska1, Sanita Ponomarjova1, Margarita Ptašņuka2,
Jevgenijs Demičevs3, Renate Demičeva3, Viesturs Boka3 and Guntars Pupelis1,2
Abstract
Background: Upper gastrointestinal bleeding (UGIB) due to peptic ulcer disease is one of the leading causes of
death in patients with non-variceal bleeding, resulting in up to 10% mortality rate, and the patient group at high
risk of rebleeding (Forrest IA, IB, and IIA) often requires additional therapy after endoscopic hemostasis. Preventive
transarterial embolization (P-TAE) after endoscopic hemostasis was introduced in our institution in 2014. The aim of
the study is an assessment of the intermediate results of P-TAE following primary endoscopic hemostasis in patients
with serious comorbid conditions and high risk of rebleeding.
Methods: During the period from 2014 to 2018, a total of 399 patients referred to our institution with a bleeding
peptic ulcer, classified as type Forrest IA, IB, or IIA with the Rockall score ≥ 5, after endoscopic hemostasis was
prospectively included in two groups—P-TAE group and control group, where endoscopy alone (EA) was
performed. The P-TAE patients underwent flow-reducing left gastric artery or gastroduodenal artery embolization
according to the ulcer type. The rebleeding rate, complications, frequency of surgical interventions, transfused
packed red blood cells (PRBC), amount of fresh frozen plasma (FFP), and mortality rate were analyzed.
Results: From 738 patients with a bleeding peptic ulcer, 399 were at high risk for rebleeding after endoscopic
hemostasis. From this cohort, 58 patients underwent P-TAE, and 341 were allocated to the EA. A significantly lower
rebleeding rate was observed in the P-TAE group, 3.4% vs. 16.2% in the EA group; p = 0.005. The need for surgical
intervention reached 10.3% vs. 20.6% in the P-TAE and EA groups accordingly; p = 0.065. Patients that underwent P-
TAE required less FFP, 1.3 unit vs. 2.6 units in EA; p = 0.0001. The mortality rate was similar in groups with a
tendency to decrease in the P-TAE group, 5.7% vs. 8.5% in EA; p = 0.417.
Conclusion: P-TAE is a feasible and safe procedure, and it may reduce the rebleeding rate and the need for
surgical intervention in patients with a bleeding peptic ulcer when the rebleeding risk remains high after primary
endoscopic hemostasis.
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Background
The reported incidence of UGIB in the USA and other
countries is still between 48 and 160 cases per 100,000
adults per year, reaching a 14% associated mortality, in-
creased hospital admissions and hospitalization costs [1, 2].
All improvements in the medical and endoscopic treat-
ments are not sufficiently effective in treating the aging
population with comorbid conditions that often have con-
comitant treatment with non-steroidal anti-inflammatory
or anti-clotting drugs [3]. Peptic ulcer bleeding is seen pre-
dominantly among the elderly, with 68% of patients over
the age of 60 and 27% over the age of 80 [2]. Elderly people
with multiple comorbidities are among those who may fail
endoscopic hemostasis and are poor candidates for
surgery [4]. Several options are recommended when
rebleeding happens, including emergent repeated endos-
copy or surgical intervention [5, 6]. TAE has been success-
fully used for bleeding control, especially in old and
multimorbid patients [7]. The preventive mode of transar-
terial embolization (TAE) has been used successfully as an
additional option to decrease the rebleeding rate after
endoscopic hemostasis [8]. The goal of P-TAE is a reduc-
tion of flow in the ulcer area by embolization of large ves-
sels, such as the left gastric artery or gastroduodenal
artery, secondary to ulcer localization in the gastric fundus,
antral, pyloric, or duodenal part avoiding a superselective
embolization of the vessel feeding the ulcer. This method
is technically easier to perform, and it allows avoiding is-
chemic complications. In a large study analyzing more
than 1500 hospital admissions, TAE or surgery was neces-
sary for 5.4% patients; half of them were operated on and
another half underwent TAE. A significant part of TAE
was done in a preventive mode, reaching a 12.5% mortality
rate after TAE and 25.6% after surgery, while the rebleed-
ing rate was 25% after TAE and 16.3% after surgery. The
authors conclude that TAE should be the preferred
hemostatic method when endoscopy fails [9]; other au-
thors report similar conclusions [10, 11]. Preventive TAE
after primary endoscopic hemostasis has been practiced in
our institution since 2014. The reduction in the rebleeding
rate after preventive TAE encouraged us to continue using
this method. The aim of the study is an assessment of the
intermediate results of preventive TAE following primary
endoscopic hemostasis in patients with serious comorbid
conditions and high rebleeding risk.
Methods
The primary outcome of the study is the rebleeding rate,
and the secondary outcomes are the complication rate
and mortality. The preparation of the study included an
analysis of the medical charts of 922 patients who were
emergently admitted to the Riga East University Hospital
with UGIB during the period from 2014 to 2018. A
bleeding peptic ulcer classified as Forrest Ia, Ib, IIa, or
IIb and the Rockall score ≥ 5 after primary endoscopic
hemostasis were the main criteria for the inclusion in
the study. P-TAE was considered for patients who were
at high risk for postoperative mortality due to their age
and comorbidities. Those who underwent the preventive
mode of TAE were included in the P-TAE group. The
control EA group consisted of similar patients who only
underwent endoscopic hemostasis or patients who did
not agree to undergo P-TAE with a similar prognosis of
high rebleeding risk after endoscopic hemostasis and
similar comorbid conditions. The exclusion criteria in-
cluded a hemodynamically unstable patient with a high
dependency for ICU support, an increased risk of severe
complications associated with the duration of TAE, and
a systemic introduction of contrast media. The partici-
pants were enrolled and assigned to their treatment by
the consensus among the consultant surgeon, consultant
radiologist, and duty endoscopy specialist. Endoscopic
combination therapy (injection of diluted adrenaline 1:
10,000, treatment with a heater probe, and/or hemoclip)
followed by a 72-h infusion of esomeprozole (80 mg
bolus followed by 8 mg/h) was applied to all patients [5].
Patients were closely monitored at ICU.
Technical approach
All patients with evidence of UGIB after admission under-
went endoscopic combination therapy followed by a 72-h
infusion of esomeprazole. Those who had high rebleeding
risk after primary endoscopic hemostasis were considered
for additional hemostasis including the surgical or re-
peated endoscopic approach. According to the consensus
of the consultant surgeon, consultant radiologist, and duty
endoscopy specialist, the alternative TAE approach was
recommended to a selective group of patients. Patients
who were at high risk for rebleeding and were not candi-
dates for emergent surgical intervention due to a critical
comorbid status were selected for P-TAE within 24 h of a
successful primary endoscopic hemostasis. Visceral angi-
ography and TAE were performed by the invasive radiolo-
gist. The technical goal of P-TAE was the embolization of
the left gastric artery or gastroduodenal artery (depending
on the ulcer localization) within 24 h of endoscopic
hemostasis, achieving a decrease of the arterial flow in the
tissue beneath the ulcer. In cases with the ulcer localized
in the smaller or greater curvature or the gastric fundus,
the left gastric artery was obliterated; in cases of gastric
antral, pyloric, or duodenal ulcers, the gastroduodenal ar-
tery was embolized [8, 12]. Rebleeding was defined as the
presence of hematemesis, blood from the nasogastric tube,
or melena associated with a fall in hemoglobin of more
than 0.8 g/dl (not explained by hemodilution) or arterial
hypotension after primary endoscopy. If therapeutic en-
doscopy was insufficient to control the bleeding (technic-
ally difficult primary therapeutic endoscopy or signs of
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exsanguination), TAE or surgical hemostasis could be per-
formed without being preceded by repeat endoscopy. The
complication rate, recurrence of bleeding, and the need
for repeat endoscopic therapy or surgery were the vari-
ables for the statistical analysis in groups. Hospital stay, in-
cluding the duration of the intensive care stay, and in-
hospital mortality rate among the groups were analyzed.
The study was approved by the local research ethics com-
mittee and followed the Declaration of Helsinki. All au-
thors had access to the study data and have reviewed and
approved the final manuscript.
Statistical analysis
Interval data are presented as the mean value with the
standard deviation (mean ± SD). A comparison of linear
data was performed using the Mann-Whitney U test. A
comparison of nominal data was performed using Pear-
son’s chi-squared test. P < 0.005 was considered as sta-
tistically significant with a confidence interval of 95%.
The statistical analysis of data was performed with the
IMB SPSS Statistics version 23.
Results
Cohort
During the 5-year period, 922 patients were presented to
Riga East University Hospital with UGIB. Of all, 738 pa-
tients had a bleeding peptic ulcer, and 399 of them had an
ulcer classified as Forrest Ia, Ib, IIa, or IIb, and the Rockall
score ≥ 5, corresponding to the high rebleeding risk
category. The mean age of patients in the P-TAE group
was 70.9 ± 15.5 years vs. 66.4 ± 14.5 years in the EA group
(p = 0.028) (Table 1). There was no statistically significant
difference in the gender and comorbid conditions of the
patients, including cardiac, pulmonary, renal, or cerebral
disease and the presence of cancer. The mean ASA score
in the P-TAE group was 4.4 ± 0.6, and in the EA group,
the ASA score was 3.7 ± 0.7 (p ≤ 0.001).
Preventive embolization
In total, 52 (13%) patients experienced rebleeding after
primary treatment. Definitive hemostasis was achieved
surgically in 39 patients, with TAE in two and repeated
endoscopy in 11 patients.
From the whole cohort, 58 (14.5%) patients had critical
comorbidities, severely increasing the risk of surgery in
case of rebleeding, and they were selected for preventive
TAE after a successful primary endoscopic hemostasis
(P-TAE group). The control group (EA) consisted of 341
patients statistically selected by the SPSS 21 program
complying with the same criteria and comorbid condi-
tion status as the P-TAE group.
Endoscopic findings
The endoscopic findings revealed a similar type of ulcer
size and distribution, with a mean size 304.7 ± 586.9
mm2 vs. 126.5 ± 254.6 mm2, p = 0.073, most commonly
Forrest IIb type—37.9% vs. 48.7% (p = 0.167). There was
no statistically significant difference in hemoglobin levels
and erythrocyte counts in the P-TAE and EA groups
(Table 2). The median Rockall score was 7 in both
groups (p = 0.597). No statistically significant difference
in any parameters was observed comparing patients who
underwent preventive TAE and those who underwent
surgery.
Outcomes
The rebleeding rate was lower in the P-TAE group, 3.4%
vs. 16.2% (p = 0.005) (Table 3). Six patients (10.3%, p =
0.065) from the P-TAE group required surgical interven-
tion; in two of them, the indication was recurrent bleeding,
and in four, surgical intervention was indicated because of
a large-size or high-risk ulcer. Preventive TAE stabilized
the patient condition before surgical intervention. From the
EA group, 71 patients (20.6%, p = 0.065) required surgical
intervention, 35 because of recurrent bleeding, 16 because
of a large ulcer, and 6 due to failed endoscopic hemostasis
(Table 3). Transfusion support was needed for the majority
of patients. The mean amount of transfused packed red
Table 1 Patient characteristics
Characteristics P-TAE EA p value
n = 58 n = 341
Age, years, mean ± SD 70.9 ± 12.5 66.4 ± 14.5 0.028
Gender/male, no of pts 32 (55.7%) 190 (55.2%) 0.938
Comorbidities, no of pts 41 (70.7%) 262 (76.8%) 0.321
Heart disease, no of pts 39 (67.2%) 240 (70.4%) 0.644
Kidney disease, no of pts 9 (15.5%) 58 (17.0%) 0.852
Liver disease, no of pts 5 (8.6%) 29 (8.5%) 0.982
Cancer, no of pts 4 (6.9%) 18 (5.3%) 0.622
Diabetes mellitus, no of pts 9 (15.8%) 61 (17.9%) 0.680
Respiratory disease, no of pts 6 (10.3%) 48 (14.1%) 0.434
Cerebral disease, no of pts 16 (27.6%) 70 (20.5%) 0.231
ASA score, points, mean ± SD 4.4 ± 0.6 3.7 ± 0.7 < 0.001
Table 2 Ulcer characteristics
Characteristics P-TAE EA p value
Ulcer size, mm, mean ± SD 304.7 ± 586.9 126.5 ± 254.6 0.073
Forrest IA, no of pts 6 (10.3%) 40 (11.7%) 0.167
Forrest IB, no of pts 8 (13.8%) 53 (15.5%) 0.167
Forrest IIA, no of pts 22 (37.9%) 82 (24.0%) 0.167
Forrest IIB, no of pts 22 (37.9%) 166 (48.7%) 0.167
HGB, g/dL, mean ± SD 8.6 ± 2.6 9.2 ± 3.1 0.176
RBC, ×1012/L, mean ± SD 2.9 ± 0.8 3.1 ± 1 0.197
INR, ratio, mean ± SD 1.3 ± 0.8 1.6 ± 5.7 0.732
Rockall score, points, mean ± SD 6.9 ± 1.4 6.9 ± 1.3 0.597
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blood cells (PRBC) was bigger in the P-TAE group than the
EA group, p = 0.002. The mean amount of transfused FFP
was lower in the P-TAE group, p = 0.001 (Table 3). No
ischemic complications were observed in patients after
preventive TAE. A similar mean ICU stay was necessary
in both groups (3.5 ± 2.2 vs 4 ± 3.5 (p = 0.300)). No dif-
ference in the mean hospital stay was observed in both
groups (p = 0.759). No statistically significant difference
was observed in the mortality rates in both groups 5.7%
vs. 8.5%, p = 0.417 (Table 3). Preventive TAE allowed
achieving a significantly lower rebleeding risk than in
the control group.
Discussion
TAE has become popular in the treatment of non-vari-
ceal UGIB in the past two decades. It can be used as a
bleeding control method in case of failed endoscopy or
as a method to prevent recurrent bleeding after a suc-
cessful primary endoscopic therapy [9, 13]. In this study,
TAE was used as a preventive tool in patients at high
risk of recurrent bleeding after primary endoscopy.
The mean age of patients who underwent preventive
TAE was 70.9 ± 12.5 years, which is higher than reported
by other authors. [9, 14]. Spiliopoulos et al. reported a mean
age of 74 years for patients undergoing TAE in their retro-
spective study [13]. The patient characteristics in the re-
cently reported study by Lau et al. are similar to the results
of the present study considering the age and characteristics
of the ulcer. In Asian trials, a predominance of male pa-
tients is reported; contrary to that, European studies report
a proportion of gender similar to our results [9, 13, 14].
Risk assessment is an indisputable part of the manage-
ment strategy in patients with acute gastrointestinal bleed-
ing. Even considering the latest progress in endoscopic,
surgical, and interventional radiology, there is still a rather
high rate of rebleeding—up to 20%—as well as deaths ran-
ging from 5 to 10% particularly in unselected patients. Risk
factor identification predicting a high risk of rebleeding is
one of the ways for outcome improvement in patients who
are poor candidates for surgery [10, 11, 15]. Several criteria
have been proposed for the stratification of high- and low-
risk patients. The criteria include the physiologic response
to bleeding: acute upper gastrointestinal bleeding and a
substantial loss of intravascular volume, resting tachycar-
dia, hypotension (systolic blood pressure, < 100 mm Hg),
or postural changes (an increase in the pulse rate) and the
importance of endoscopic findings (ulcer size and com-
pleteness of endoscopic hemostasis) [2, 15]. The Glasgow-
Blatchford score is widely recommended for the prediction
of outcomes and the timing of medical intervention includ-
ing emergent endoscopy in patients with upper gastrointes-
tinal bleeding [6, 16–20]. The Rockall score is calculated
based on the clinical variables indicating the urgency of
endoscopic intervention and evidence of stigmata of bleed-
ing [2, 21]. The Glasgow-Blatchford score and the Rockall
score are superior considering their sensitivity in predicting
the rebleeding rate [15, 17]. Factors like hemoglobin levels,
ulcer size, arterial pressure, heart rate, and ASA score were
taken into account when making a decision about further
therapy after a successful primary endoscopy.
TAE may be used as both a bleeding control method
in case of failed endoscopic treatment and a prophylactic
method after a successful primary endoscopy [9, 14]. A
high risk of recurrent bleeding after primary endoscopic
hemostasis and a critical physiologic status associated
with serious comorbidities were the characteristic fea-
tures of the enrolled patient cohort determining the high
surgical intervention risk and favoring the less aggressive
preventive TAE approach. The evaluation of the study
results demonstrated that preventive embolization re-
duces the recurrent bleeding rate and the need for sur-
gery in our cohort. Recent European and Asian studies
also show that patients who underwent prophylactic
angiographic embolization had a lower recurrent bleed-
ing rate and need for surgery [14, 22].
The type, size, and localization of the ulcer are very
important selection criteria [13]. The incidence of high-
risk Forrest Ia, Ib, IIa, and IIb type ulcers is different in
several reports. Lau et al. included only patients with
Forrest Ia, Ib, and IIa ulcers having more patients with
Forrest Ib, but a similar number of patients with Forrest
Ia ulcers. Laursen et al. also reported more than a third
of patients with Forrest Ib ulcers, Nykanen et al. reported
a prevalence of Forrest Ia and Ib ulcers in the majority of
patients [9, 14, 23]. In our study, Forrest Ia and Ib ulcers
were observed in 27% and Forrest IIa and IIb ulcers in
73% of the included patients. The difference in ulcer pres-
entation could be associated with the number of patients
who were referred late and a different interpretation of
the endoscopic findings by our endoscopy specialists.
One of the main criteria for high-risk patient selection is
the Rockall score. According to our previous study, the
Rockall score ≥ 5 was associated with a high risk of recur-
rent bleeding in patients with Forrest Ia–IIb ulcers [24].
Mille et al. in their study performed preventive embolization
in high-risk patients with Forrest Ia–IIc ulcers and the
Table 3 Outcomes
Characteristics P-TAE EA p value
ICU stay days, mean ± SD 3.5 ± 2.2 4 ± 3.5 0.300
Hospital stay days, mean ± SD 10.2 ± 8 9.8 ± 6.8 0.670
Re-bleeding, n% 2 (3.4%) 50 (16.2%) 0.005
Mortality, n% 3 (5.7%) 28 (8.5%) 0.417
PRBC, units, mean ± SD 6.6 ± 2.2 3.6 ± 2.5 0.002
FFP, units, mean ± SD 1.3 ± 1 2.6 ± 1.7 0.001
Surgery, n% 6 (10.3%) 71 (20.6%) 0.065
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Rockall score ≥ 6 [22]. A similar approach was used for the
selection of candidates for preventive TAE in the
present study.
Our results showed that patients who underwent pre-
ventive TAE required more PRBC than EA (6.6 ± 2.2
units vs. 3.6 ± 1.7 units, p = 0.002). It may be explained
by a lower hemoglobin level at presentation comparing
with the EA. Mille et al. observed similar results in their
trial comparing patients who underwent prophylactic
TAE (3.9 units) and endoscopic treatment group (1.7
units). They described the endoscopic treatment group
as relatively healthier [22]. Lau et al. reported a median
of two transfused blood units in both groups. Laursen et
al. reported a median of 4.3 blood transfusion units for
the TAE group and 4.9 units for the control group, but
no statistical difference was observed [14]. However, the
transfusion rate of FFP was significantly higher in the
EA than in the P-TAE group. The reason is not clear,
and the explanation reported by other authors that the
control group may have higher INR at presentation time
is not consistent with our results showing no difference
in the level of INR in groups.
The incidence of recurrent bleeding after preventive
embolization is crucial for the outcome. Lau et al. re-
ported a rebleeding rate of 6.2% for patients who under-
went preventive embolization and 11.4% after standard
treatment without a statistical significance. Laursen et al.
reported rebleeding rates of 4% in the group that under-
went supplementary TAE and 14% for the control group
[14, 23]. Our results demonstrated a significant differ-
ence in favor of TAE (3.4% vs. 16.2%, p = 0.005). Surgi-
cal intervention was the only option remaining for 2
patients who had rebleeding after preventive TAE, sig-
nificantly less compared to the control group. The ICU
stay, hospital stay, and mortality were not different in
our study; similar results were reported by Lau et al. and
Nykanen et al. [9, 14]. Laursen et al. reported shorter
median hospital stays for patients after TAE [23]. Our
strategy resulted in a comparable 5.7% and 8.5% mortal-
ity rate between groups similar to reports from other
authors [9, 14, 23].
Limitations of the study
The most significant limitation of our study is the lack
of randomization because the interventional radiologist
and interventional radiology personnel are not available
during the night and on weekends. The unequal distri-
bution of patients between both groups is the next major
limitation; however, improving availability of invasive
radiology service, a randomized trial is justified.
Conclusion
Preventive TAE is feasible and safe in patients with a
bleeding peptic ulcer when the rebleeding risk remains
high after endoscopic hemostasis, reducing the rebleeding
rate and the need for surgical intervention. Even if surgery
is needed due to a high-risk peptic ulcer, preventive TAE
allows preparing the patient for the operation by minimiz-
ing rebleeding in the pre-operative period. Preventive
TAE should be the preferred method in elderly and multi-
morbid patients who are poor candidates for surgery and
have a high risk of post-operative mortality.
Abbreviations
EA: Endoscopy alone group; FFP: Fresh frozen plasma; HGB: Hemoglobin;
ICU: Intensive care unit; INR: International normalized ratio; PRBC: Packed red
blood cells; P-TAE: Preventive transarterial embolization group; RBC: Red





AK conducted the research/study, analyzed the data, and wrote the manuscript.
PI, AKr, and SP performed the radiologic assesment and TAE. MPt, JD, and RD
conduced the research/study and analyzed the data. VB supervised the study.
GP supervised the research/study, analyzed the data, and review the
manuscript. All authors have read and approved the final manuscript.
Funding
No funding to declare.
Availability of data and materials
Not applicable.





The authors declare that they have no competing interests.
Author details
1Riga East University Hospital, University of Latvia, Riga, Latvia. 2Riga Stradins
University, Riga, Latvia. 3University of Latvia, Riga, Latvia.
Received: 31 July 2019 Accepted: 29 August 2019
References
1. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P, et al.
International consensus recommendations on the management of patients
with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;
152(2):101–13.
2. Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a
peptic ulcer. N Engl J Med. 2008;359(9):928–37.
3. Loffroy RF, Abualsaud BA, Lin MD, Rao PP. Recent advances in endovascular
techniques for management of acute nonvariceal upper gastrointestinal
bleeding. World J Gastrointest Surg. 2011;3:89–100.
4. Laine LCLINICALPRACTICE. Upper gastrointestinal bleeding due to a peptic
ulcer. N Engl J ed. 2016;374(24):2367–76.
5. Acute Upper Gastrointestinal Bleeding: Management. National Clinical
Guideline Centre (UK). In: Royal College of Physicians (UK). London: National
Institute for Health and Clinical Excellence: Guidance; 2012.
6. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, et al.
Diagnosis and management of nonvariceal upper gastrointestinal
hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE)
Guideline. Endoscopy. 2015;47:a1–a46.
Kaminskis et al. World Journal of Emergency Surgery           (2019) 14:45 Page 5 of 6
7. Bagdarasov VV, Bagdarasova EA, Chernookov AI, Atayan AA, Karchevsky EV,
Bagdarasova DV. Endovascular arterial embolization for duodenal bleeding
as an alternative to surgical approach. Khirurgiia (Mosk). 2016;(2):45–50.
8. Kuyumcu G, Latich I, Hardman RL, Fine GC, Oklu R, Quencer KB.
Gastroduodenal embolization: indications, technical pearls, and outcomes. J
Clin Med. 2018;7(5):101.
9. Nykanen T, Peltola E, Kylanpaa L, Udd M. Bleeding gastric and duodenal
ulcers: case-control study comparing angioembolization and surgery. Scand
J Gastroenterol. 2017;52(5):523–30.
10. Wong TC, Wong KT, Chiu PW, Teoh AY, Yu SC, Au KW, Lau JY. A comparison
of angiographic embolization with surgery after failed endoscopic
hemostasis to bleeding peptic ulcers. Gastrointest Endosc. 2011;73(5):900–8.
11. Mirsadraee S, Tirukonda P, Nicholson A, Everett SM, McPherson SJ.
Embolization for non-variceal upper gastrointestinal tract haemorrhage: a
systematic review. Clin Radiol. 2011;66(6):500–9.
12. Kaminskis A, Ivanova P, Ponomarjova S, Mukans M, Boka V, Pupelis G. Rockall
score larger than 7 as a reliable criterion for the selection of indications for
preventive transarterial embolization in a subgroup of high-risk elderly patients
after primary endoscopic hemostasis for non-variceal upper gastrointestinal
bleeding. Gastroenterology Res. 2017 Dec;10(6):339–46.
13. Spiliopoulos S, Inchingolo R, Lucatelli P, Iezzi R, Diamantopoulos A, Posa A, Barry
B, Ricci C, Cini M, Konstantos C, Palialexis K, Reppas L, Trikola A, Nardella M, Adam
A, Brountzos E. Transcatheter arterial embolization for bleeding peptic ulcers: a
multicenter study. Cardiovasc Intervent Radiol. 2018 Sep;41(9):1333–9.
14. Lau JYW, Pittayanon R, Wong KT, Pinjaroen N, Chiu PWY, Rerknimitr R,
Holster IL, Kuipers EJ, Wu KC, Au KWL, Chan FKL, Sung JJY. Prophylactic
angiographic embolisation after endoscopic control of bleeding to high-risk
peptic ulcers: a randomised controlled trial. Gut. 2019 May;68(5):796–803.
15. Camus M, Jensen DM, Kovacs TO, Jensen ME, Markovic D, Gornbein J.
Independent risk factors of 30-day outcomes in 1264 patients with peptic
ulcer bleeding in the USA: large ulcers do worse. Aliment Pharmacol Ther.
2016;43(10):1080–9.
16. Greenspoon J, Barkun A. A summary of recent recommendations on the
management of patients with nonvariceal upper gastrointestinal bleeding.
Pol Arch Med Wewn. 2010 Sep;120(9):341–6.
17. Martinez-Cara JG, Jimenez-Rosales R, Ubeda-Munoz M, de Hierro ML, de
Teresa J, Redondo-Cerezo E. Comparison of AIMS65, Glasgow-Blatchford
score, and Rockall score in a European series of patients with upper
gastrointestinal bleeding: performance when predicting in-hospital and
delayed mortality. United Eur Gastroenterol J. 2016;4(3):371–9.
18. Stanley AJ, Laine L, Dalton HR, Ngu JH, Schultz M, Abazi R, Zakko L, et al.
Comparison of risk scoring systems for patients presenting with upper
gastrointestinal bleeding: international multicentre prospective study. BMJ.
2017;356:i6432.
19. Bryant RV, Kuo P, Williamson K, Yam C, Schoeman MN, Holloway RH,
Nguyen NQ. Performance of the Glasgow-Blatchford score in predicting
clinical outcomes and intervention in hospitalized patients with upper GI
bleeding. Gastrointest Endosc. 2013;78(4):576–83.
20. Mokhtare M, Bozorgi V, Agah S, Nikkhah M, Faghihi A, Boghratian A, Shalbaf
N, et al. Comparison of Glasgow-Blatchford score and full Rockall score
systems to predict clinical outcomes in patients with upper gastrointestinal
bleeding. Clin Exp Gastroenterol. 2016;9:337–43.
21. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute
upper gastrointestinal haemorrhage. Gut. 1996;38(3):316–21.
22. Mille M, Huber J, Wlasak R, Engelhardt T, Hillner Y, Kriechling H, Aschenbach
R, Ende K, Scharf JG, Puls R, Stier A. Prophylactic transcatheter arterial
embolization after successful endoscopic hemostasis in the management of
bleeding duodenal ulcer. J Clin Gastroenterol. 2015 Oct;49(9):738–45.
23. Laursen SB, Hansen JM, Andersen PE, Schaffalitzky de muckadell OB.
Supplementary arterial embolization an option in high-risk ulcer bleeding–a
randomized study. Scand J Gastroenterol. 2014;49:75–83.
24. Kaminskis A, Kratovska A, Ponomarjova S, Tolstova A, Mukans M, Stabina S,
Gailums R, Bernsteins A, Ivanova P, Boka V, Pupelis G. Preventive transarterial
embolization in upper nonvariceal gastrointestinal bleeding. World J Emerg
Surg. 2017;12:3.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kaminskis et al. World Journal of Emergency Surgery           (2019) 14:45 Page 6 of 6
